Discussion Forums > Thalassemia Major

Gene Therepy

<< < (3/3)

Andy Battaglia:
What I find ironic about Bluebird is that they are preventing their PR department from giving them the PR that could put them in a more positive view in the public's eye.

Canadian_Family:
By no means this is an investment advice, I am trying to assess the viability of BlueBird to continue in operation (which eventually helps Thalassemia patients).

bluebird bio to Present at Three Upcoming Health Care Conferences

For details : http://www.nasdaq.com/press-release/bluebird-bio-to-present-at-three-upcoming-health-care-conferences-20140501-01726#ixzz31FVUPVaL

I checked the volume of share trade, it is not high. Bluebird is featured in Investopidia as one of three companies to profit from.

The liquidity is strong and revenues have grown since 2011.

Conclusion

I believe this company is not strapped for cash. However, there is always a responsibility to generate profits for shareholders, which means expensive treatments for patients.

Andy Battaglia:
They are well financed, but no one is allowed to talk about what they're doing. The lawyers are in charge. Can't say that's a good thing.

leonardo:
But how we can talk about mutagens drug for beta thal when gene therapy is on second step of trial?  .....Ivano Argiolas from Italy is still testing therapy......

Navigation

[0] Message Index

[*] Previous page